Ticker >

Bafna Pharma share price

Bafna Pharmaceuticals Ltd.

NSE: BAFNAPH BSE: 532989 SECTOR: Pharmaceuticals & Drugs  19k   33   4

76.50
-0.99 (-1.28%)
BSE: 28 Mar 04:01 PM

Price Summary

Today's High

₹ 78

Today's Low

₹ 76.5

52 Week High

₹ 125.55

52 Week Low

₹ 77.3

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

180.97 Cr.

Enterprise Value

196.08 Cr.

No. of Shares

2.37 Cr.

P/E

16.07

P/B

2.28

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  33.57

CASH

7.81 Cr.

DEBT

22.92 Cr.

Promoter Holding

88.43 %

EPS (TTM)

₹  4.76

Sales Growth

35.48%

ROE

16.75 %

ROCE

16.12%

Profit Growth

117.34 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year35.48%
3 Year39.52%
5 Year19.58%

Profit Growth

1 Year117.34%
3 Year34.81%
5 Year21.88%

ROE%

1 Year16.75%
3 Year15.93%
5 Year-7.9%

ROCE %

1 Year16.12%
3 Year11.72%
5 Year2.26%

Debt/Equity

0.3121

Price to Cash Flow

36.54

Interest Cover Ratio

6.70097173144876

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2023 88.43 0
Sep 2023 88.74 0
Jun 2023 90 0
Mar 2023 90 0
Dec 2022 90.02 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 39.519534765191% for the Past 3 years.
  • Company’s PEG ratio is 0.136939077579309.
  • The company has an efficient Cash Conversion Cycle of 37.4691485154226 days.
  • The company has a high promoter holding of 88.43%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.35724669540887.

 Limitations

  • The company has a low EBITDA margin of 3.00101155501107% over the past 5 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 34.22 42.24 41.95 40.68 28.44
Total Expenditure 31.18 34.62 35.65 36.67 30.52
Operating Profit 3.04 7.62 6.3 4 -2.08
Other Income 1.93 0.26 1.87 0.16 0.98
Interest 0.58 0.7 0.6 0.44 0.58
Depreciation 1.4 1.53 1.21 1.24 1.27
Exceptional Items 0 0 0 0 0
Profit Before Tax 3 5.65 6.35 2.48 -2.94
Tax 0 0.28 0 0 0
Profit After Tax 3 5.37 6.35 2.48 -2.94
Adjusted EPS (Rs) 1.27 2.27 2.68 1.05 -1.24

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 43.63 42.47 71.22 85.14 115.35
Total Expenditure 56.69 41.24 60.92 73.24 99.63
Operating Profit -13.07 1.23 10.3 11.9 15.72
Other Income 0.39 0.26 0.75 1.76 3.27
Interest 2.13 0.1 0.74 0.79 2.04
Depreciation 3.42 3.27 4.48 5.49 5.33
Exceptional Items 0 0 0 -2.16 0
Profit Before Tax -18.23 -1.88 5.83 5.22 11.62
Tax 1.5 0 0 0 0.28
Net Profit -19.73 -25.2 5.83 5.22 11.34
Adjusted EPS (Rs.) -8.34 -7.94 2.46 2.21 4.79

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 23.66 2.37 23.66 23.66 23.66
Total Reserves -2.86 48.58 33.11 38.31 49.8
Borrowings 22.99 3.02 2.5 5.32 8.43
Other N/C liabilities 6.21 0 2.89 0.85 1.22
Current liabilities 70.65 17.1 24.31 22.01 46.48
Total Liabilities 120.64 71.06 86.47 90.14 129.58
Assets
Net Block 37.02 34.97 35.97 38.85 40.23
Capital WIP 0 0.21 0.83 0 0
Intangible WIP 0 0 0 0 1.5
Investments 1.43 0 0 0 0
Loans & Advances 32.95 0 0 0.42 0.54
Other N/C Assets 1 0 0 0 0
Current Assets 48.24 35.88 49.67 50.88 87.31
Total Assets 120.64 71.06 86.47 90.14 129.58
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations -18.23 -1.88 5.83 5.19 11.77
Adjustment 5.42 -20.22 3.82 5.5 7.88
Changes in Assets & Liabilities 11.71 -12.17 -23.25 -0.8 -14.57
Tax Paid 0 0 0 -0.17 -0.13
Operating Cash Flow -1.1 -34.27 -13.61 9.73 4.95
Investing Cash Flow 3.53 32.77 -5.35 -6.54 -7.49
Financing Cash Flow -2.44 7.27 12.28 -4.81 10.18
Net Cash Flow 0 5.78 -6.68 -1.63 7.64

Corporate Actions

Investors Details

PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
promoters 90.02 90.00 90.00 88.74 88.43
amri bai bafna 0.01 0.01 0.01 0.01 0.01
bafna mahaveer chand 0.04 0.02 0.03 0.03 0.03
naveenbafna m 0.18 0.18 0.18 0.18 0.18
p paras bafna 0.21 0.21 0.21 0.21 0.21
sasikala bafna. - 0.01 0.01 0.01 0.01
srjr lifesciences llp 89.57 89.57 89.57 88.30 87.99
sasikala bafna 0.01 - - - -
PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
investors 9.98 10.00 10.00 11.26 11.57
investor education and pr... - 0.01 - - 0.01
monarch networth finserve... - - - - 1.35
investor education and pr... 0.01 - 0.01 0.01 -
monarch networth finserve... 1.35 1.35 1.35 1.35 -

Annual Reports

Ratings & Research Reports

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Bafna Pharma - Quaterly Results12 Feb 2024, 5:08PM Bafna Pharma - Quaterly Results12 Feb 2024, 5:08PM Bafna Pharma - Quaterly Results12 Feb 2024, 5:08PM Bafna Pharmaceuticals informs about board meeting2 Feb 2024, 3:07PM Bafna Pharmaceuticals informs about resignation of director23 Sep 2023, 2:23PM Bafna Pharma - Quaterly Results12 Aug 2023, 12:09PM Bafna Pharma - Quaterly Results12 Aug 2023, 12:09PM Bafna Pharmaceuticals informs about certificate13 Jul 2023, 12:08PM Bafna Pharma - Quaterly Results27 May 2023, 4:01PM Bafna Pharmaceuticals informs about board meeting4 Apr 2023, 2:16PM Bafna Pharma - Quaterly Results8 Feb 2023, 2:11PM Bafna Pharma - Quaterly Results8 Feb 2023, 2:11PM Bafna Pharma - Quaterly Results8 Feb 2023, 2:11PM Bafna Pharmaceuticals informs about voting results29 Jul 2022, 4:30PM Bafna Pharma - Quaterly Results26 May 2022, 2:55PM Bafna Pharma - Quaterly Results26 May 2022, 2:55PM Bafna Pharmaceuticals informs about compliance certificate13 Apr 2022, 5:11PM Bafna Pharmaceuticals informs about PCS certificate11 Apr 2022, 3:12PM Bafna Pharmaceuticals informs about change in CS cum CO21 Mar 2022, 5:04PM Bafna Pharmaceuticals informs about disclosure9 Mar 2022, 2:16PM Bafna Pharma - Quaterly Results10 Feb 2022, 4:26PM Bafna Pharma - Quaterly Results10 Feb 2022, 4:26PM Bafna Pharmaceuticals informs about board meeting15 Sep 2021, 4:47PM Bafna Pharmaceuticals gets UK-MHRA approval for packaging lines4 May 2021, 10:00AM Bafna Pharmaceuticals informs about voting results of AGM1 Aug 2020, 3:20PM

Bafna Pharma Stock Price Analysis and Quick Research Report. Is Bafna Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Bafna Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Bafna Pharma cash from the operating activity was Rs 4.9525 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Bafna Pharma has a Debt to Equity ratio of 0.3121 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Bafna Pharma , the EPS growth was 117.34083076365 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Bafna Pharma has OPM of 13.624285760109 % which is a bad sign for profitability.
     
  • ROE: Bafna Pharma have a average ROE of 16.7451518738605 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Bafna Pharma is Rs 78.35. One can use valuation calculators of ticker to know if Bafna Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Bafna Pharma
X